Influences shaping clinicians’ monoclonal antibody and immune checkpoint inhibitor preparation and administration management practices: A systematic review

Background: Monoclonal antibodies (mAbs) and immune checkpoint inhibitors (ICPIs) have expanded treatment options for cancer and non- malignant diseases, with reduced side effects and improved survival outcomes compared to chemotherapy. However, challenges arise with unconjugated mAbs due to unclear hazardous classifications, leading to variations in safety practices among healthcare organisations. Standardised guidelines are crucial to ensure clinician safety during preparation and administration, given the links between these agents, immune dysfunction, and increased risks.

Aim: To identify the influences shaping cancer clinicians’ awareness of safe handling, current practices, and recommended practices for those involved in the administration and preparation of unconjugated mAbs and ICPIs